Reuters logo
BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda
February 23, 2017 / 2:22 PM / 7 months ago

BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda

Feb 23 (Reuters) - Merck & Co Inc:

* Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck’s keytruda® (pembrolizumab)

* Biothera pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck’s keytruda® (pembrolizumab) Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below